SI5 Global SI5 Global
✓ Produto localizado
Medicamentos E Saúde

Invega Trinza 263mg Suspensão Injetável de Liberação Prolongada 1 Seringa Preenchida + 2 Agulhas

Invega
GTIN / EAN
7896212425679
CEST
Não informado
Conteúdo
Não informado

Dados de produto preservados no idioma original.

Invega Trinza 263mg Suspensão Injetável de Liberação Prolongada 1 Seringa Preenchida + 2 Agulhas é fabricado pela Invega, na categoria Medicamentos E Saúde, com código de barras 7896212425679. Classificado no NCM 3004.90.99 (Medicamentos (exceto os produtos das posições 30.02, 30.05 ou 30.06) constituídos por produtos misturados ou não misturados, preparados para fins terapêuticos ou profiláticos, apresentados em doses (incluindo os destinados a serem administrados por via percutânea) ou acondicionados para venda a retalho › Outros).

Fonte: SI5 Global · código registrado em Brasil · atualizado em 02/10/2026

WhatsApp

Preço base (referência): R$ 6.884,99 — coletado em paguemenos.com.br em 02/10/2026, pode não estar atualizado

Consultar este produto pela API

Código de barras

7896212425679

Código registrado em Brasil · prefixo 789

Classificação fiscal

NCM
3004.90.99Medicamentos (exceto os produtos das posições 30.02, 30.05 ou 30.06) constituídos por produtos misturados ou não misturados, preparados para fins terapêuticos ou profiláticos, apresentados em doses (incluindo os destinados a serem administrados por via percutânea) ou acondicionados para venda a retalho › Outros
Cadastro fiscal pronto para o seu ERP

NCM, CEST, CST/CSOSN, PIS/COFINS e cClassTrib do IBS/CBS deste produto para o seu regime. Até 50 produtos por dia, grátis.

Gerar cadastro fiscal

Descrição do produto

O que é Invega Trinza 263mg Suspensão Injetável de Liberação Prolongada 1 Seringa Preenchida + 2 Agulhas?

O Invega Trinza 263mg Suspensão Injetável de Liberação Prolongada 1 Seringa Preenchida + 2 Agulhas é um medicamento antipsicótico atípico de ação prolongada, apresentado como uma suspensão injetável. Sua formulação inovadora permite uma administração trimestral, ou seja, a cada três meses. Contendo o princípio ativo palmitato de paliperidona, este medicamento é indicado para o tratamento de manutenção da esquizofrenia em pacientes adultos. A terapia com Invega Trinza é iniciada apenas após o paciente ter sido adequadamente tratado e estabilizado com injeções mensais de palmitato de paliperidona por, no mínimo, quatro meses, garantindo a continuidade do controle dos sintomas e prevenindo recaídas da doença.

Conteúdo da embalagem: 1 seringa preenchida com 1,315ml de suspensão injetável de liberação prolongada + 2 agulhas de segurança.

Fabricado por: Janssen

Indicação etária: Uso adulto.

Composição Invega Trinza 263mg:

Princípio ativo: palmitato de paliperidona 410mg (equivalente a 263mg de paliperidona).

Excipientes: polissorbato 20, macrogol 4000, ácido cítrico monoidratado, fosfato de sódio monobásico monoidratado, hidróxido de sódio e água para injetáveis.

Para que serve Invega Trinza?

Invega Trinza é um medicamento antipsicótico indicado para o tratamento de manutenção da esquizofrenia em pacientes adultos. Ele é utilizado após o paciente já ter sido estabilizado com a formulação injetável mensal de palmitato de paliperidona (Invega Sustenna) por pelo menos quatro meses.

Sua principal finalidade é:

  • Manter o transtorno esquizofrênico sob controle, ajudando a gerenciar os sintomas de forma contínua.
  • Prevenir a ocorrência de recaídas, ou seja, o retorno dos sintomas agudos da doença.
  • Auxiliar no controle de sintomas característicos da esquizofrenia, como alucinações (ouvir ou ver coisas que não existem), delírios (crenças falsas), desconfiança anormal, isolamento social e discurso desorganizado.

Como devo usar Invega Trinza 263mg?

Invega Trinza deve ser administrado exclusivamente por um profissional de saúde. A aplicação não deve ser feita pelo próprio paciente. As orientações de uso são:

  • A administração é intramuscular, ou seja, profunda no músculo do deltoide (braço) ou glúteo (nádega).
  • Antes da aplicação, o profissional de saúde deve agitar a seringa vigorosamente por no mínimo 15 segundos para garantir que a suspensão esteja homogênea.
  • A dose de Invega Trinza é administrada uma vez a cada 3 meses.
  • A primeira dose do medicamento deve ser aplicada no momento em que a próxima injeção mensal de palmitato de paliperidona estaria programada.
  • É fundamental seguir o cronograma de aplicação a cada três meses para garantir a eficácia do tratamento. Não interrompa o uso sem orientação médica.

Quando não devo usar Invega Trinza?

O uso de Invega Trinza é contraindicado em situações específicas. Você não deve usar este medicamento se:

  • Tiver hipersensibilidade (alergia) conhecida à paliperidona, à risperidona ou a qualquer outro componente da fórmula.
  • For menor de 18 anos, pois a segurança e a eficácia não foram estabelecidas para esta faixa etária.

Além disso, informe seu médico sobre seu histórico de saúde, especialmente em casos de doenças cardiovasculares, diabetes, problemas renais, histórico de convulsões ou se for um paciente idoso com psicose relacionada à demência, pois existem advertências e precauções importantes para essas populações.

Ficha técnica

Medicamento
True
MarcaPropria
Não
NumeroRegistroMS
1.1236.3398.017-0
NomeSubstanciaPrincipioAtivo
Paliperidoma
DescricaoBula
%0A%09%09%09%09%09%09%3Ch2%3ELaborat%26%23xF3%3Brio%3C%2Fh2%3E%0A%3Cp%3Ejanssen%3C%2Fp%3E%0A%3Ch2%3E%20Apresenta%26%23xE7%3B%26%23xE3%3Bo%20INVEGA%20%3C%2Fh2%3E%0A%3Cp%3EComprimidos%20revestidos%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20prolongada%20de%203%2C%206%20e%209%20mg%20em%20embalagens%20%20com%207%20e%2028%20comprimidos.%3C%2Fp%3E%0A%3Ch2%3E%20INVEGA%20%26%23x2013%3B%20Indica%26%23xE7%3B%26%23xF5%3Bes%20%3C%2Fh2%3E%0A%3Cp%3EInvega%20%26%23xE9%3B%20indicado%20para%20o%20tratamento%20da%20esquizofrenia%2C%20incluindo%20tratamento%20agudo%20e%20preven%26%23xE7%3B%26%23xE3%3Bo%20de%20recorr%26%23xEA%3Bncia.%3C%2Fp%3E%0A%3Ch2%3E%20Contra%20indica%26%23xE7%3B%26%23xF5%3Bes%20de%20INVEGA%20%3C%2Fh2%3E%0A%3Cp%3EInvega%20%26%23xE9%3B%20contra-indicado%20em%20pacientes%20com%20hipersensibilidade%20conhecida%20%26%23xE0%3B%20paliperidona%20ou%20a%20qualquer%20componente%20da%20formula%26%23xE7%3B%26%23xE3%3Bo.%20Invega%20%26%23xE9%3B%20contra-indicado%20em%20pacientes%20com%20conhecida%20hipersensibilidade%20%26%23xE0%3B%20risperidona%2C%20uma%20vez%20que%20a%20paliperidona%20corresponde%20a%20um%20metab%26%23xF3%3Blito%20ativo%20da%20risperidona.%3C%2Fp%3E%0A%20%20%20%20%20%20%20%20%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Famp-ad%3E%0A%3Ch2%3EAdvert%26%23xEA%3Bncias%3C%2Fh2%3E%0A%3Cp%3ES%26%23xED%3Bndrome%20neurol%26%23xE9%3Bptica%20maligna%20%20A%20ocorr%26%23xEA%3Bncia%20de%20s%26%23xED%3Bndrome%20neurol%26%23xE9%3Bptica%20maligna%20caracterizada%20%20por%20hipertermia%2C%20rigidez%20muscular%2C%20instabilidade%20auton%26%23xF4%3Bmica%2C%20%20altera%26%23xE7%3B%26%23xE3%3Bo%20da%20consci%26%23xEA%3Bncia%20e%20n%26%23xED%3Bveis%20elevados%20de%20creatina%20fosfoquinase%20%20t%26%23xEA%3Bm%20sido%20relatada%20com%20f%26%23xE1%3Brmacos%20antipsic%26%23xF3%3Bticos%2C%20%20incluindo%20a%20paliperidona.%20Sinais%20cl%26%23xED%3Bnicos%20adicionais%20podem%20incluir%20%20mioglobin%26%23xFA%3Bria%20(rabdomi%26%23xF3%3Blise)%20e%20insufi%20ci%26%23xEA%3Bncia%20renal%20aguda.%20%20Se%20o%20paciente%20desenvolver%20sinais%20ou%20sintomas%20indicativos%20de%20%20s%26%23xED%3Bndrome%20neurol%26%23xE9%3Bptica%20maligna%2C%20todos%20os%20antipsic%26%23xF3%3Bticos%2C%20incluindo%20%20Invega%2C%20devem%20ser%20descontinuados.%20%20Discinesia%20tardia%20%20F%26%23xE1%3Brmacos%20com%20propriedades%20antagonistas%20de%20receptor%20dopamin%26%23xE9%3Brgico%20%20t%26%23xEA%3Bm%20sido%20associados%20%26%23xE0%3B%20indu%26%23xE7%3B%26%23xE3%3Bo%20de%20discinesia%20tardia%20%20caracterizada%20por%20movimentos%20involunt%26%23xE1%3Brios%2C%20r%26%23xED%3Btmicos%2C%20predominantemente%20%20da%20l%26%23xED%3Bngua%20e%2Fou%20da%20face.%20Se%20surgirem%20sinais%20ou%20%20sintomas%20de%20discinesia%20tardia%2C%20a%20descontinua%26%23xE7%3B%26%23xE3%3Bo%20de%20todos%20os%20f%26%23xE1%3Brmacos%20antipsic%26%23xF3%3Bticos%2C%20incluindo%20Invega%2C%20deve%20ser%20considerada.%20%20Intervalo%20QT%20%20Assim%20como%20outros%20antipsic%26%23xF3%3Bticos%2C%20deve-se%20ter%20cautela%20quando%20%20Invega%26%23x99%3B%20%26%23xE9%3B%20prescrito%20a%20pacientes%20com%20hist%26%23xF3%3Brico%20de%20arritmias%20%20card%26%23xED%3Bacas%2C%20em%20pacientes%20com%20s%26%23xED%3Bndrome%20cong%26%23xEA%3Bnita%20do%20prolongamento%20%20do%20intervalo%20QT%20e%20em%20uso%20concomitante%20com%20medicamentos%20%20que%20conhecidamente%20prolongam%20o%20intervalo%20QT.%20%20Hiperglicemia%20%20Casos%20raros%20de%20eventos%20adversos%20relacionados%20%26%23xE0%3B%20glicose%20%20foram%20relatados%20em%20estudos%20cl%26%23xED%3Bnicos%20com%20Invega%26%23x99%3B%20.%20Recomenda-%20%20se%20o%20monitoramento%20cl%26%23xED%3Bnico%20apropriado%20em%20pacientes%20%20diab%26%23xE9%3Bticos%20e%20em%20pacientes%20com%20fatores%20de%20risco%20para%20o%20desenvolvimento%20%20de%20diabetes%20mellitus.%20%20Hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%20%20A%20paliperidona%20pode%20induzir%20hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%20em%20alguns%20%20pacientes%20em%20fun%26%23xE7%3B%26%23xE3%3Bo%20de%20sua%20atividade%20de%20bloqueador%20alfa.%20Invega%20%20%26%23x99%3B%20deve%20ser%20usado%20com%20cautela%20em%20pacientes%20com%20hist%26%23xF3%3Bria%20%20de%20doen%26%23xE7%3Ba%20cardiovascular%20(como%20por%20exemplo%2C%20insufi%20ci%26%23xEA%3Bncia%20%20card%26%23xED%3Baca%2C%20infarto%20ou%20isquemia%20do%20mioc%26%23xE1%3Brdio%2C%20anormalidades%20da%20condu%26%23xE7%3B%26%23xE3%3Bo)%2C%20doen%26%23xE7%3Ba%20vascular%20cerebral%20ou%20condi%26%23xE7%3B%26%23xF5%3Bes%20que%20%20predisponham%20o%20paciente%20%26%23xE0%3B%20hipotens%26%23xE3%3Bo%20(como%20por%20exemplo%2C%20%20desidrata%26%23xE7%3B%26%23xE3%3Bo%2C%20hipovolemia%20e%20tratamento%20com%20medicamentos%20%20anti-hipertensivos).%20%20Crises%20epil%26%23xE9%3Bpticas%20%20Da%20mesma%20forma%20que%20outros%20antipsic%26%23xF3%3Bticos%2C%20Invega%26%23x99%3B%20deve%20%20ser%20usado%20com%20cautela%20em%20pacientes%20com%20hist%26%23xF3%3Bria%20de%20crises%20%20epil%26%23xE9%3Bpticas%20ou%20outras%20condi%26%23xE7%3B%26%23xF5%3Bes%20que%20reduzem%20potencialmente%20%20o%20limiar%20convulsivo.%20%20Potencial%20para%20obstru%26%23xE7%3B%26%23xE3%3Bo%20gastrintestinal%20%20Uma%20vez%20que%20o%20comprimido%20de%20Invega%26%23x99%3B%20n%26%23xE3%3Bo%20se%20deforma%20e%20n%26%23xE3%3Bo%20%20altera%20sua%20forma%20no%20trato%20gastrintestinal%2C%20Invega%26%23x99%3B%20n%26%23xE3%3Bo%20deve%20%20ser%20administrado%20a%20pacientes%20com%20estreitamento%20gastrintestinal%20%20grave%20preexistente%20(patol%26%23xF3%3Bgico%20ou%20iatrog%26%23xEA%3Bnico)%20ou%20em%20pacientes%20%20com%20disfagia%20ou%20difi%20culdade%20signifi%20cante%20para%20deglutir%20comprimidos.%20%20Tem%20havido%20relatos%20raros%20de%20sintomas%20de%20obstru%26%23xE7%3B%26%23xE3%3Bo%20em%20%20pacientes%20com%20hist%26%23xF3%3Bria%20de%20estreitamento%20associado%20%26%23xE0%3B%20ingest%26%23xE3%3Bo%20%20de%20f%26%23xE1%3Brmacos%20em%20formula%26%23xE7%3B%26%23xF5%3Bes%20n%26%23xE3%3Bo%20deform%26%23xE1%3Bveis%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20%20controlada.%20Devido%20ao%20desenho%20da%20forma%20farmac%26%23xEA%3Butica%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20prolongada%2C%20Invega%26%23x99%3B%20s%26%23xF3%3B%20deve%20ser%20usado%20em%20pacientes%20%20capazes%20de%20deglutir%20o%20comprimido%20inteiro.%20%20Pacientes%20idosos%20com%20dem%26%23xEA%3Bncia%20%20Invega%26%23x99%3B%20n%26%23xE3%3Bo%20foi%20estudado%20nessa%20popula%26%23xE7%3B%26%23xE3%3Bo%20de%20pacientes%2C%20%20desta%20forma%20o%20medicamento%20n%26%23xE3%3Bo%20%26%23xE9%3B%20recomendado%20para%20pacientes%20%20idosos%20com%20dem%26%23xEA%3Bncia.%20%20Mortalidade%20geral%20%20Em%20uma%20meta-an%26%23xE1%3Blise%20de%2017%20estudos%20cl%26%23xED%3Bnicos%20controlados%2C%20%20pacientes%20idosos%20com%20dem%26%23xEA%3Bncia%20tratados%20com%20outros%20f%26%23xE1%3Brmacos%20%20antipsic%26%23xF3%3Bticos%20at%26%23xED%3Bpicos%2C%20incluindo%20a%20risperidona%2C%20aripiprazol%2C%20%20olanzapina%20e%20quetiapina%2C%20tiveram%20um%20risco%20aumentado%20de%20%20mortalidade%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20ao%20placebo.%20%20Eventos%20adversos%20vascular%20cerebral%20%20Em%20estudos%20cl%26%23xED%3Bnicos%20controlados%20com%20placebo%20em%20pacientes%20%20idosos%20com%20dem%26%23xEA%3Bncia%2C%20tratados%20com%20f%26%23xE1%3Brmacos%20antipsic%26%23xF3%3Bticos%20%20at%26%23xED%3Bpicos%2C%20incluindo%20a%20risperidona%2C%20aripiprazol%20e%20olanzapina%2C%20houve%20%20uma%20incid%26%23xEA%3Bncia%20maior%20de%20eventos%20adversos%20vascular%20cerebral%20%20(acidente%20vascular%20cerebral%20e%20epis%26%23xF3%3Bdios%20de%20isquemia%20transit%26%23xF3%3Bria)%2C%20%20incluindo%20casos%20fatais%2C%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20ao%20placebo.%20%20Doen%26%23xE7%3Ba%20de%20Parkinson%20e%20dem%26%23xEA%3Bncia%20com%20corpos%20de%20Lewy%20%20O%20m%26%23xE9%3Bdico%20deve%20pesar%20os%20riscos%20em%20rela%26%23xE7%3B%26%23xE3%3Bo%20aos%20benef%26%23xED%3Bcios%20ao%20%20prescrever%20antipsic%26%23xF3%3Bticos%2C%20incluindo%20Invega%26%23x99%3B%2C%20para%20pacientes%20%20com%20doen%26%23xE7%3Ba%20de%20Parkinson%20ou%20dem%26%23xEA%3Bncia%20com%20corpos%20de%20Lewy%2C%20%20uma%20vez%20que%20ambos%20os%20grupos%20podem%20estar%20sob%20risco%20aumentado%20%20de%20desenvolver%20s%26%23xED%3Bndrome%20neurol%26%23xE9%3Bptica%20maligna%2C%20assim%20%20como%20de%20ter%20uma%20sensibilidade%20aumentada%20a%20medicamentos%20%20antipsic%26%23xF3%3Bticos.%20A%20manifesta%26%23xE7%3B%26%23xE3%3Bo%20dessa%20sensibilidade%20aumentada%20%20pode%20incluir%20confus%26%23xE3%3Bo%2C%20embotamento%2C%20instabilidade%20postural%20%20com%20quedas%20frequentes%2C%20al%26%23xE9%3Bm%20dos%20sintomas%20extrapiramidais.%20%20Priapismo%20%20Tem%20sido%20relatado%20que%20f%26%23xE1%3Brmacos%20com%20efeitos%20de%20bloqueio%20alfaadren%26%23xE9%3Brgico%20%20induzem%20o%20priapismo.%20Embora%20nenhum%20caso%20de%20%20priapismo%20tenha%20sido%20relatado%20nos%20estudos%20cl%26%23xED%3Bnicos%20com%20Invega%20%20%26%23x99%3B%2C%20a%20paliperidona%20compartilha%20essa%20atividade%20farmacol%26%23xF3%3Bgica%20%20e%2C%20portanto%2C%20pode%20estar%20associada%20a%20esse%20risco.%20%20Controle%20da%20temperatura%20corporal%20%20A%20interrup%26%23xE7%3B%26%23xE3%3Bo%20da%20capacidade%20do%20organismo%20de%20reduzir%20a%20%20temperatura%20corporal%20foi%20atribu%26%23xED%3Bda%20a%20agentes%20antipsic%26%23xF3%3Bticos.%20%20Recomenda-se%20cuidado%20apropriado%20ao%20prescrever%20Invega%26%23x99%3B%20para%20pacientes%20que%20ir%26%23xE3%3Bo%20se%20expor%20a%20condi%26%23xE7%3B%26%23xF5%3Bes%20que%20possam%20%20contribuir%20para%20o%20aumento%20da%20temperatura%20corporal%2C%20como%20por%20%20exemplo%20exerc%26%23xED%3Bcio%20extenuante%2C%20exposi%26%23xE7%3B%26%23xE3%3Bo%20ao%20calor%20extremo%2C%20%20uso%20de%20medica%26%23xE7%3B%26%23xE3%3Bo%20concomitante%20com%20atividade%20anticolin%26%23xE9%3Brgica%2C%20%20ou%20sujeito%20a%20desidrata%26%23xE7%3B%26%23xE3%3Bo.%20%20Efeito%20antiem%26%23xE9%3Btico%20%20Um%20efeito%20antiem%26%23xE9%3Btico%20foi%20observado%20em%20estudos%20pr%26%23xE9%3B-cl%26%23xED%3Bnicos%20%20com%20a%20paliperidona.%20Esse%20efeito%2C%20se%20ocorrer%20em%20seres%20humanos%2C%20%20pode%20mascarar%20os%20sinais%20e%20sintomas%20de%20dose%20excessiva%20%20com%20certos%20f%26%23xE1%3Brmacos%20ou%20de%20condi%26%23xE7%3B%26%23xF5%3Bes%20tais%20como%20obstru%26%23xE7%3B%26%23xE3%3Bo%20%20intestinal%2C%20s%26%23xED%3Bndrome%20de%20Reye%20e%20tumor%20cerebral.%20%20Efeitos%20sobre%20a%20capacidade%20de%20dirigir%20ve%26%23xED%3Bculos%20e%20utilizar%20%20m%26%23xE1%3Bquinas%20%20Invega%26%23x99%3B%20pode%20interferir%20com%20as%20atividades%20que%20requerem%20%20alerta%20mental%20e%20pode%20ocasionar%20efeitos%20visuais%20(veja%20o%20item%20%20%26%23x93%3BRea%26%23xE7%3B%26%23xF5%3Bes%20Adversas%26%23x94%3B).%20%20Durante%20o%20tratamento%2C%20o%20paciente%20n%26%23xE3%3Bo%20deve%20dirigir%20ve%26%23xED%3Bculos%20%20ou%20operar%20m%26%23xE1%3Bquinas%2C%20pois%20sua%20habilidade%20e%20aten%26%23xE7%3B%26%23xE3%3Bo%20%20podem%20estar%20prejudicadas.%3C%2Fp%3E%0A%3Ch2%3EIntera%26%23xE7%3B%26%23xF5%3Bes%20medicamentosas%20de%20INVEGA%3C%2Fh2%3E%0A%3Cp%3ERecomenda-se%20cautela%20ao%20prescrever%20Invega%20com%20medicamentos%20%20conhecidos%20por%20prolongar%20o%20intervalo%20QT.%20%20Potencial%20de%20Invega%20afetar%20outros%20f%26%23xE1%3Brmacos%20%20N%26%23xE3%3Bo%20%26%23xE9%3B%20esperado%20que%20a%20paliperidona%20cause%20intera%26%23xE7%3B%26%23xF5%3Bes%20farmacocin%26%23xE9%3Bticas%20%20clinicamente%20importantes%20com%20f%26%23xE1%3Brmacos%20que%20s%26%23xE3%3Bo%20%20metabolizados%20pelas%20isoenzimas%20do%20citocromo%20P-450.%20Estudos%20%20in%20vitro%20em%20microssomas%20hep%26%23xE1%3Bticos%20humanos%20mostraram%20que%20%20a%20paliperidona%20n%26%23xE3%3Bo%20inibe%20de%20forma%20substancial%20o%20metabolismo%20%20de%20f%26%23xE1%3Brmacos%20metabolizados%20pelas%20isoenzimas%20do%20citocromo%20%20P-450%2C%20incluindo%20CYP1A2%2C%20CYP2A6%2C%20CYP2C8%2F9%2F10%2C%20CYP2D6%2C%20%20CYP2E1%2C%20CYP3A4%20e%20CYP3A5.%20Portanto%2C%20n%26%23xE3%3Bo%20se%20espera%20que%20%20a%20paliperidona%20iniba%2C%20de%20forma%20clinicamente%20relevante%2C%20a%20depura%26%23xE7%3B%26%23xE3%3Bo%20%20de%20f%26%23xE1%3Brmacos%20que%20s%26%23xE3%3Bo%20metabolizados%20por%20essas%20vias%20%20metab%26%23xF3%3Blicas.%20N%26%23xE3%3Bo%20%26%23xE9%3B%20esperado%2C%20tamb%26%23xE9%3Bm%2C%20que%20a%20paliperidona%20%20tenha%20propriedades%20indutoras%20de%20enzimas.%20%20Em%20altas%20concentra%26%23xE7%3B%26%23xF5%3Bes%2C%20a%20paliperidona%20%26%23xE9%3B%20um%20fraco%20inibidor%20da%20%20glicoprote%26%23xED%3Bna-P%20(P-gp).%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20dados%20in%20vivo%20dispon%26%23xED%3Bveis%20e%20a%20%20relev%26%23xE2%3Bncia%20cl%26%23xED%3Bnica%20%26%23xE9%3B%20desconhecida.%20%20Devido%20aos%20efeitos%20prim%26%23xE1%3Brios%20da%20paliperidona%20sobre%20o%20sistema%20%20nervoso%20central%2C%20Invega%26%23x99%3B%20deve%20ser%20usado%20com%20cautela%20em%20%20combina%26%23xE7%3B%26%23xE3%3Bo%20com%20outros%20f%26%23xE1%3Brmacos%20de%20a%26%23xE7%3B%26%23xE3%3Bo%20central%20e%20%26%23xE1%3Blcool.%20A%20%20paliperidona%20pode%20antagonizar%20o%20efeito%20da%20levodopa%20e%20outros%20%20agonistas%20dopamin%26%23xE9%3Brgicos.%20%20Devido%20ao%20seu%20potencial%20para%20induzir%20hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%2C%20%20pode%20ser%20observado%20um%20efeito%20aditivo%20quando%20Invega%26%23x99%3B%20%26%23xE9%3B%20%20administrado%20com%20outros%20agentes%20terap%26%23xEA%3Buticos%20que%20possuem%20%20esse%20potencial.%20%20Potencial%20para%20outros%20f%26%23xE1%3Brmacos%20afetarem%20Invega%26%23x99%3B%20%20A%20paliperidona%20n%26%23xE3%3Bo%20%26%23xE9%3B%20um%20substrato%20da%20CYP1A2%2C%20CYP2A6%2C%20%20CYP2C9%2C%20CYP2C19%20e%20CYP3A5.%20Isso%20sugere%20que%20n%26%23xE3%3Bo%20%26%23xE9%3B%20prov%26%23xE1%3Bvel%20%20a%20ocorr%26%23xEA%3Bncia%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20com%20inibidores%20ou%20indutores%20%20dessas%20isoenzimas.%20Embora%20estudos%20in%20vitro%20indiquem%20que%20a%20%20CYP2D6%20e%20a%20CYP3A4%20podem%20estar%20minimamente%20envolvidas%20%20no%20metabolismo%20da%20paliperidona%2C%20n%26%23xE3%3Bo%20h%26%23xE1%3B%20indica%26%23xE7%3B%26%23xF5%3Bes%20in%20vitro%20%20nem%20in%20vivo%20de%20que%20essas%20isoenzimas%20tenham%20um%20papel%20signifi%20cante%20no%20metabolismo%20da%20paliperidona.%20Estudos%20in%20vitro%20%20demonstraram%20que%20a%20paliperidona%20%26%23xE9%3B%20um%20substrato%20da%20glicoprote%26%23xED%3Bna%20%20P.%20%20A%20paliperidona%20%26%23xE9%3B%20metabolizada%20com%20extens%26%23xE3%3Bo%20limitada%20pela%20%20CYP2D6%20(veja%20Propriedades%20Farmacocin%26%23xE9%3Bticas%3A%20metabolismo%20%20e%20elimina%26%23xE7%3B%26%23xE3%3Bo).%20N%26%23xE3%3Bo%20foram%20observados%20efeitos%20clinicamente%20%20relevantes%20sobre%20a%20farmacocin%26%23xE9%3Btica%20da%20paliperidona%2C%20em%20um%20%20estudo%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20em%20indiv%26%23xED%3Bduos%20saud%26%23xE1%3Bveis%20no%20qual%20Invega%20%20%26%23x99%3B%20foi%20administrado%20concomitantemente%20com%20paroxetina%2C%20%20um%20potente%20inibidor%20da%20CYP2D6.%20%20A%20co-adminstra%26%23xE7%3B%26%23xE3%3Bo%20de%20Invega%26%23x99%3B%20uma%20vez%20ao%20dia%20com%20carbamazepina%20%20200%20mg%20duas%20vezes%20ao%20dia%20causou%20uma%20diminui%26%23xE7%3B%26%23xE3%3Bo%20%20de%20aproximadamente%2037%25%20no%20estado%20de%20equil%26%23xED%3Bbrio%20m%26%23xE9%3Bdio%20da%20%20Cm%26%23xE1%3Bx%20e%20AUC%20da%20paliperidona.%20Esta%20diminui%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE9%3B%20causada%20por%20%20um%20grau%20substancial%2C%20por%20um%20aumento%20de%2035%25%20na%20depura%26%23xE7%3B%26%23xE3%3Bo%20%20renal%20da%20paliperidona%20provavelmente%20como%20um%20resultado%20da%20%20indu%26%23xE7%3B%26%23xE3%3Bo%20da%20glicoprote%26%23xED%3Bna%20P%20renal%20pela%20carbamazepina.%20Uma%20%20menor%20diminui%26%23xE7%3B%26%23xE3%3Bo%20na%20quantidade%20de%20droga%20excretada%20inalterada%20%20na%20urina%20sugere%20que%20h%26%23xE1%3B%20um%20pequeno%20efeito%20sobre%20o%20%20metabolismo%20da%20CYP%20ou%20biodisponibilidade%20da%20paliperidona%20nifi%20cante%20no%20metabolismo%20da%20paliperidona.%20Estudos%20in%20vitro%20%20demonstraram%20que%20a%20paliperidona%20%26%23xE9%3B%20um%20substrato%20da%20glicoprote%26%23xED%3Bna%20P.%20%20%20A%20paliperidona%20%26%23xE9%3B%20metabolizada%20com%20extens%26%23xE3%3Bo%20limitada%20pela%20CYP2D6%20(veja%20Propriedades%20Farmacocin%26%23xE9%3Bticas%3A%20metabolismo%20e%20elimina%26%23xE7%3B%26%23xE3%3Bo).%20N%26%23xE3%3Bo%20foram%20observados%20efeitos%20clinicamente%20%20relevantes%20sobre%20a%20farmacocin%26%23xE9%3Btica%20da%20paliperidona%2C%20em%20um%20estudo%20de%20intera%26%23xE7%3B%26%23xE3%3Bo%20em%20indiv%26%23xED%3Bduos%20saud%26%23xE1%3Bveis%20no%20qual%20Invega%20%26%23x99%3B%20foi%20administrado%20concomitantemente%20com%20paroxetina%2C%20um%20potente%20inibidor%20da%20CYP2D6.%20%20A%20co-adminstra%26%23xE7%3B%26%23xE3%3Bo%20de%20Invega%26%23x99%3B%20uma%20vez%20ao%20dia%20com%20carbamazepina%20200%20mg%20duas%20vezes%20ao%20dia%20causou%20uma%20diminui%26%23xE7%3B%26%23xE3%3Bo%20de%20aproximadamente%2037%25%20no%20estado%20de%20equil%26%23xED%3Bbrio%20m%26%23xE9%3Bdio%20da%20Cm%26%23xE1%3Bx%20e%20AUC%20da%20paliperidona.%20Esta%20diminui%26%23xE7%3B%26%23xE3%3Bo%20%26%23xE9%3B%20causada%20por%20um%20grau%20substancial%2C%20por%20um%20aumento%20de%2035%25%20na%20depura%26%23xE7%3B%26%23xE3%3Bo%20%20renal%20da%20paliperidona%20provavelmente%20como%20um%20resultado%20da%20indu%26%23xE7%3B%26%23xE3%3Bo%20da%20glicoprote%26%23xED%3Bna%20P%20renal%20pela%20carbamazepina.%20Uma%20menor%20diminui%26%23xE7%3B%26%23xE3%3Bo%20na%20quantidade%20de%20droga%20excretada%20inalterada%20na%20urina%20sugere%20que%20h%26%23xE1%3B%20um%20pequeno%20efeito%20sobre%20o%20metabolismo%20da%20CYP%20ou%20biodisponibilidade%20da%20paliperidona.%3C%2Fp%3E%0A%3Ch2%3ERea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%2F%20efeitos%20colaterais%20de%20INVEGA%3C%2Fh2%3E%0A%3Cp%3EDados%20de%20estudos%20cl%26%23xED%3Bnicos%20%20A%20seguran%26%23xE7%3Ba%20de%20Invega%20foi%20avaliada%20em%201205%20pacientes%20com%20esquizofrenia%20que%20participaram%20em%203%20estudos%20cl%26%23xED%3Bnicos%20de%20dose%20fixa%2C%20duplo-cegos%2C%20controlados%20com%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo.%20A%20informa%26%23xE7%3B%26%23xE3%3Bo%20apresentada%20a%20seguir%20para%20os%20pacientes%20tratados%20com%20Invega%20%26%23xE9%3B%20baseada%20nos%20dados%20%20agrupados%20de%20pacientes%20que%20receberam%20Invega%20na%20dose%20di%26%23xE1%3Bria%20recomendada%20de%203%2C%206%2C%209%20ou%2012%20mg.%20Os%20termos%20para%20sistemas%20corporais%20e%20evento%20adverso%2Frea%26%23xE7%3B%26%23xE3%3Bo%20adversa%20s%26%23xE3%3Bo%20baseados%20no%20dicion%26%23xE1%3Brio%20MedDRA.%20%20Dados%20de%20estudos%20cl%26%23xED%3Bnicos%3A%20Eventos%20adversos%20em%20estudos%20de%20curta-dura%26%23xE7%3B%26%23xE3%3Bo%2C%20com%20dose-fi%20xa%2C%20controlados%20com%20placebo.%20%20A%20Tabela%201%20mostra%20todos%20os%20eventos%20adversos%20emergentes%20durante%20o%20tratamento%2C%20independente%20da%20causalidade%2C%20com%20incid%26%23xEA%3Bncia%20%3D1%25%20dos%20pacientes%20tratados%20com%20Invega%20nesses%20estudos%2C%20e%20para%20os%20quais%20a%20incid%26%23xEA%3Bncia%20nos%20pacientes%20tratados%20com%20Invega%20foi%20maior%20que%20nos%20pacientes%20tratados%20com%20placebo.%20%20Tabela%201%3A%20Eventos%20adversos%20emergentes%20do%20tratamento%2C%20independente%20da%20causalidade%2C%20relatados%20por%20%26gt%3B%3D%201%25%20dos%20pacientes%20com%20esquizofrenia%20em%20qualquer%20grupo%20Invega%20e%20que%20ocorreram%20em%20incid%26%23xEA%3Bncia%20maior%20que%20no%20grupo%20placebo%20nos%203%20estudos%20cl%26%23xED%3Bnicos%20de%20dose%20fi%20xa%2C%20duplo-cegos%2C%20controlados%20com%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo.%20%20%20%20Sistema%20corporal%20ou%20classe%20de%20%26%23xF3%3Brg%26%23xE3%3Bo%20Placebo%203%20mg%206%20mg%209%20mg%2012%20mg%20%20(N%3D355)%20(N%3D127)%20(N%3D235)%20(N%3D246)%20(N%3D242)%20%20n%20(%25)%20n%20(%25)%20n%20(%25)%20n%20(%25)%20n%20(%25)%20%20Transtornos%20card%26%23xED%3Bacos%20%20Bloqueio%20atrioventricular%20de%201.%26%23xBA%3B%20grau%205%20(1%2C4)%202%20(1%2C6)%200%206%20(2%2C4)%202%20(0%2C8)%20%20Bradicardia%203%20(0%2C8)%200%203%20(1%2C3)%203%20(1%2C2)%204%20(1%2C7)%20%20Bloqueio%20de%20ramo%206%20(1%2C7)%204%20(3%2C1)%203%20(1%2C3)%207%20(2%2C8)%201%20(0%2C4)%20%20Palpita%26%23xE7%3B%26%23xF5%3Bes%200%202%20(1%2C6)%202%20(0%2C9)%200%203%20(1%2C2)%20%20Arritmia%20sinusal%200%203%20(2%2C4)%202%20(0%2C9)%202%20(0%2C8)%201%20(0%2C4)%20%20Taquicardia%20sinusal%2015%20(4%2C2)%2011%20(8%2C7)%209%20(3%2C8)%2010%20(4%2C1)%2017%20(7%2C0)%20%20Taquicardia%2010%20(2%2C8)%203%20(2%2C4)%2017%20(7%2C2)%2018%20(7%2C3)%2018%20(7%2C4)%20%20%20%20Sistema%20corporal%20ou%20classe%20de%20%26%23xF3%3Brg%26%23xE3%3Bo%20Placebo%203%20mg%206%20mg%209%20mg%2012%20mg%20%20(N%3D355)%20(N%3D127)%20(N%3D235)%20(N%3D246)%20(N%3D242)%20%20n%20(%25)%20n%20(%25)%20n%20(%25)%20n%20(%25)%20n%20(%25)%20%20Transtornos%20oculares%20%20Olho%20seco%200%202%20(1%2C6)%200%201%20(0%2C4)%201%20(0%2C4)%20%20Rota%26%23xE7%3B%26%23xE3%3Bo%20ocular%200%200%200%205%20(2%2C0)%200%20%20Vis%26%23xE3%3Bo%20borrada%204%20(1%2C1)%201%20(0%2C8)%201%20(0%2C4)%200%205%20(2%2C1)%20%20Transtornos%20gastrintestinais%20%20Dor%20abdominal%203%20(0%2C8)%200%204%20(1%2C7)%202%20(0%2C8)%202%20(0%2C8)%20%20Dor%20abdominal%20alta%202%20(0%2C6)%201%20(0%2C8)%206%20(2%2C6)%205%20(2%2C0)%204%20(1%2C7)%20%20Diarr%26%23xE9%3Bia%208%20(2%2C3)%201%20(0%2C8)%202%20(0%2C9)%203%20(1%2C2)%206%20(2%2C5)%20%20Transtornos%20gastrintestinais%20%20Boca%20seca%202%20(0%2C6)%203%20(2%2C4)%208%20(3%2C4)%202%20(0%2C8)%207%20(2%2C9)%20%20Dispepsia%2014%20(3%2C9)%203%20(2%2C4)%206%20(2%2C6)%205%20(2%2C0)%2012%20(5%2C0)%20%20N%26%23xE1%3Busea%2019%20(5%2C4)%208%20(6%2C3)%209%20(3%2C8)%2010%20(4%2C1)%2010%20(4%2C1)%20%20Hipersecre%26%23xE7%3B%26%23xE3%3Bo%20salivar%201%20(0%2C3)%200%201%20(0%2C4)%203%20(1%2C2)%2010%20(4%2C1)%20%20Desconforto%20estomacal%201%20(0%2C3)%202%20(1%2C6)%203%20(1%2C3)%201%20(0%2C4)%202%20(0%2C8)%20%20Dor%20de%20dente%204%20(1%2C1)%202%20(1%2C6)%205%20(2%2C1)%206%20(2%2C4)%205%20(2%2C1)%20%20V%26%23xF4%3Bmito%2017%20(4%2C8)%202%20(1%2C6)%206%20(2%2C6)%209%20(3%2C7)%2012%20(5%2C0)%20%20Transtornos%20gerais%20%20Astenia%203%20(0%2C8)%202%20(1%2C6)%201%20(0%2C4)%205%20(2%2C0)%205%20(2%2C1)%20%20Fadiga%205%20(1%2C4)%202%20(1%2C6)%202%20(0%2C9)%204%20(1%2C6)%205%20(2%2C1)%20%20Pirexia%204%20(1%2C1)%201%20(0%2C8)%201%20(0%2C4)%205%20(2%2C0)%204%20(1%2C7)%20%20Infec%26%23xE7%3B%26%23xF5%3Bes%20e%20inflama%26%23xE7%3B%26%23xF5%3Bes%20%20Bronquite%201%20(0%2C3)%200%203%20(1%2C3)%201%20(0%2C4)%202%20(0%2C8)%20%20Nasofaringite%2010%20(2%2C8)%204%20(3%2C1)%205%20(2%2C1)%204%20(1%2C6)%206%20(2%2C5)%20%20Rinite%201%20(0%2C3)%200%203%20(1%2C3)%200%201%20(0%2C4)%20%20Infec%26%23xE7%3B%26%23xF5%3Bes%20e%20inflama%26%23xE7%3B%26%23xF5%3Bes%20%20Infec%26%23xE7%3B%26%23xE3%3Bo%20vias%20a%26%23xE9%3Breas%20superiores%202%20(0%2C6)%201%20(0%2C8)%202%20(0%2C9)%203%20(1%2C2)%202%20(0%2C8)%20%20Infec%26%23xE7%3B%26%23xE3%3Bo%20viral%201%20(0%2C3)%200%201%20(0%2C4)%202%20(0%2C8)%203%20(1%2C2)%20%20Ferimento%2C%20envenenamento%20e%20%20complica%26%23xE7%3B%26%23xF5%3Bes%20de%20procedimento%20%20Queda%201%20(0%2C3)%200%203%20(1%2C3)%200%200%20%20Exames%20%20Aumento%20de%20alanina%20aminotransferase%204%20(1%2C1)%201%20(0%2C8)%204%20(1%2C7)%202%20(0%2C8)%202%20(0%2C8)%20%20Aumento%20de%20creatina%20fosfoquinase%205%20(1%2C4)%201%20(0%2C8)%204%20(1%2C7)%200%201%20(0%2C4)%20%20Aumento%20da%20insulina%20no%20sangue%202%20(0%2C6)%203%20(2%2C4)%203%20(1%2C3)%202%20(0%2C8)%201%20(0%2C4)%20%20Aumento%20da%20press%26%23xE3%3Bo%20arterial%202%20(0%2C6)%203%20(2%2C4)%201%20(0%2C4)%201%20(0%2C4)%203%20(1%2C2)%20%20Aumento%20de%20triglic%26%23xE9%3Brides%20no%20sangue%201%20(0%2C3)%202%20(1%2C6)%201%20(0%2C4)%200%200%20%20ECG%3A%20intervalo%20QT%20corrigido%20prolongado*%209%20(2%2C5)%204%20(3%2C1)%209%20(3%2C8)%207%20(2%2C8)%2012%20(5%2C0)%20%20ECG%3A%20onda%20T%20anormal%204%20(1%2C1)%203%20(2%2C4)%202%20(0%2C9)%204%20(1%2C6)%202%20(0%2C8)%20%20ECG%3A%20invers%26%23xE3%3Bo%20da%20onda%20T%203%20(0%2C8)%200%201%20(0%2C4)%203%20(1%2C2)%202%20(0%2C8)%20%20ECG%20anormal%200%200%200%204%20(1%2C6)%202%20(0%2C8)%20%20Aumento%20da%20frequ%26%23xEA%3Bncia%20card%26%23xED%3Baca%202%20(0%2C6)%204%20(3%2C1)%202%20(0%2C9)%201%20(0%2C4)%203%20(1%2C2)%20%20Aumento%20do%20pept%26%23xED%3Bdeo-C%20da%20insulina%203%20(0%2C8)%202%20(1%2C6)%203%20(1%2C3)%202%20(0%2C8)%200%20%20Redu%26%23xE7%3B%26%23xE3%3Bo%20do%20peso%203%20(0%2C8)%202%20(1%2C6)%200%200%200%20%20Aumento%20do%20peso%205%20(1%2C4)%201%20(0%2C8)%200%204%20(1%2C6)%204%20(1%2C7)%20%20Transtornos%20metab%26%23xF3%3Blicos%20e%20nutricionais%20%20Redu%26%23xE7%3B%26%23xE3%3Bo%20do%20apetite%200%202%20(1%2C6)%201%20(0%2C4)%201%20(0%2C4)%202%20(0%2C8)%20%20Aumento%20do%20apetite%201%20(0%2C3)%202%20(1%2C6)%200%203%20(1%2C2)%203%20(1%2C2)%20%20Transtornos%20m%26%23xFA%3Bsculo-esquel%26%23xE9%3Bticos%20%20e%20de%20tecido%20conjuntivo%20%20Artralgia%203%20(0%2C8)%200%204%20(1%2C7)%202%20(0%2C8)%200%20%20Lombalgia%203%20(0%2C8)%201%20(0%2C8)%202%20(0%2C9)%203%20(1%2C2)%205%20(2%2C1)%20%20Rigidez%20muscular%200%201%20(0%2C8)%200%203%20(1%2C2)%201%20(0%2C4)%20%20Dor%20no%20pesco%26%23xE7%3Bo%201%20(0%2C3)%200%200%200%203%20(1%2C2)%20%20Dor%20em%20extremidade%204%20(1%2C1)%200%202%20(0%2C9)%200%205%20(2%2C1)%20%20Dor%20no%20ombro%200%201%20(0%2C8)%203%20(1%2C3)%202%20(0%2C8)%202%20(0%2C8)%20%20Transtornos%20do%20sistema%20nervoso%20%20Acatisia%2014%20(3%2C9)%205%20(3%2C9)%207%20(3%2C0)%2020%20(8%2C1)%2023%20(9%2C5)%20%20Vertigem%2014%20(3%2C9)%207%20(5%2C5)%2011%20(4%2C7)%2011%20(4%2C5)%2012%20(5%2C0)%20%20Discinesia%203%20(0%2C8)%200%201%20(0%2C4)%201%20(0%2C4)%204%20(1%2C7)%20%20Distonia%20%202%20(0%2C6)%2001%20(0%2C8)%203%20(1%2C3)%209%20(3%2C7)%209%20(3%2C7)%20%20Transtorno%20extrapiramidal%208%20(2%2C3)%206%20(4%2C7)%205%20(2%2C1)%2017%20(6%2C9)%2018%20(7%2C4)%20%20Cefal%26%23xE9%3Bia%2042%20(11%2C8)%2014%20(11%2C0)%2029%20(12%2C3)%2034%20(13%2C8)%2035%20(14%2C5)%20%20Hipertonia%204%20(1%2C1)%203%20(2%2C4)%203%20(1%2C3)%2010%20(4%2C1)%208%20(3%2C3)%20%20Parkinsonismo%200%200%201%20(0%2C4)%205%20(2%2C0)%203%20(1%2C2)%20%20Seda%26%23xE7%3B%26%23xE3%3Bo%2013%20(3%2C7)%201%20(0%2C8)%2012%20(5%2C1)%208%20(3%2C3)%2015%20(6%2C2)%20%20Sonol%26%23xEA%3Bncia%2012%20(3%2C4)%206%20(4%2C7)%208%20(3%2C4)%2017%20(6%2C9)%2011%20(4%2C5)%20%20S%26%23xED%3Bncope%201%20(0%2C3)%201%20(0%2C8)%202%20(0%2C9)%203%20(1%2C2)%201%20(0%2C4)%20%20Tremor%2012%20(3%2C4)%204%20(3%2C1)%206%20(2%2C6)%2011%20(4%2C5)%208%20(3%2C3)%20%20Transtornos%20psiqui%26%23xE1%3Btricos%20%20Agressividade%204%20(1%2C1)%202%20(1%2C6)%201%20(0%2C4)%203%20(1%2C2)%202%20(0%2C8)%20%20Ansiedade%2029%20(8%2C2)%2012%20(9%2C4)%2016%20(6%2C8)%2014%20(5%2C7)%2011%20(4%2C5)%20%20Depress%26%23xE3%3Bo%201%20(0%2C3)%200%203%20(1%2C3)%201%20(0%2C4)%201%20(0%2C4)%20%20Pesadelos%200%200%201%20(0%2C4)%203%20(1%2C2)%201%20(0%2C4)%20%20Idea%26%23xE7%3B%26%23xE3%3Bo%20suicida%204%20(1%2C1)%202%20(1%2C6)%202%20(0%2C9)%201%20(0%2C4)%201%20(0%2C4)%20%20Transtornos%20respirat%26%23xF3%3Brio%2C%20tor%26%23xE1%3Bcico%20%20e%20mediast%26%23xED%3Bnico%20%20Tosse%204%20(1%2C1)%204%20(3%2C1)%204%20(1%2C7)%207%20(2%2C8)%204%20(1%2C7)%20%20Congest%26%23xE3%3Bo%20nasal%203%20(0%2C8)%201%20(0%2C8)%203%20(1%2C3)%202%20(0%2C8)%202%20(0%2C8)%20%20Transtornos%20de%20pele%20e%20de%20tecido%20subcut%26%23xE2%3Bneo%20%20Prurido%204%20(1%2C1)%200%203%20(1%2C3)%202%20(0%2C8)%200%20%20Transtornos%20vasculares%20%20Hipotens%26%23xE3%3Bo%201%20(0%2C3)%202%20(1%2C6)%201%20(0%2C4)%202%20(0%2C8)%202%20(0%2C8)%20%20Hipotens%26%23xE3%3Bo%20ostost%26%23xE1%3Btica%203%20(0%2C8)%203%20(2%2C4)%203%20(1%2C3)%206%20(2%2C4)%209%20(3%2C7)%20%20*%20Quando%20foi%20aplicado%20um%20fator%20de%20corre%26%23xE7%3B%26%23xE3%3Bo%20apropriado%2C%20QTc%20linear%20derivado%2C%20n%26%23xE3%3Bo%20houve%20%20casos%20de%20prolongamento%20de%20QTc.%20%20Dados%20de%20estudos%20cl%26%23xED%3Bnicos%3A%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20ao%20f%26%23xE1%3Brmaco%20em%20estudos%20%20de%20curta-dura%26%23xE7%3B%26%23xE3%3Bo%2C%20com%20dose-fi%20xa%2C%20controlados%20com%20placebo.%20%20As%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20mais%20frequentes%2C%20relatadas%20por%20%3D%202%25%20dos%20pacientes%20tratados%20%20com%20Invega%20inclu%26%23xED%3Bram%3A%20cefal%26%23xE9%3Bia%20(13%2C2%25)%2C%20taquicardia%20(6%2C6%25)%2C%20acatisia%20%20(6%2C5%25)%2C%20taquicardia%20sinusal%20(5%2C5%25)%2C%20transtorno%20extrapiramidal%20(5%2C4%25)%2C%20sonol%26%23xEA%3Bncia%20%20(4%2C9%25)%2C%20vertigem%20(4%2C8%25)%2C%20seda%26%23xE7%3B%26%23xE3%3Bo%20(4%2C2%25)%2C%20tremor%20(3%2C4%25)%2C%20hipertonia%20%20(2%2C8%25)%2C%20distonia%20(2%2C6%25)%2C%20hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%20(2%2C5%25)%20e%20boca%20seca%20(2%2C4%25).%20%20As%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20que%20parecem%20estar%20relacionadas%20%26%23xE0%3B%20dose%20foram%3A%20aumento%20%20do%20peso%2C%20cefal%26%23xE9%3Bia%2C%20hipersecre%26%23xE7%3B%26%23xE3%3Bo%20salivar%2C%20v%26%23xF4%3Bmito%2C%20discinesia%2C%20acatisia%2C%20%20distonia%2C%20transtorno%20extrapiramidal%2C%20hipertonia%20e%20Parkinsonismo.%20%20As%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20descritas%20a%20seguir%20foram%20relatadas%20pelos%20pacientes%20%20com%20esquizofrenia%2C%20tratados%20com%20Invega%20(n%3D850)%20nos%203%20estudos%20cl%26%23xED%3Bnicos%20%20de%20dose%20fi%20xa%2C%20duplo-cegos%2C%20controlados%20por%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo.%20%20Os%20seguintes%20termos%20e%20frequ%26%23xEA%3Bncias%20foram%20aplicados%3A%20muito%20comum%20%20(%3D10%25)%2C%20comum%20(frequente)%20(%3D1%25%20a%20%26lt%3B10%25)%2C%20incomum%20(infrequente)%20(%3D0%2C1%25%20%20a%20%26lt%3B1%25)%2C%20raro%20(%3D0%2C01%25%20a%20%26lt%3B0%2C1%25)%20e%20muito%20raro%20(%26lt%3B0%2C01%25).%20A%20maioria%20dos%20eventos%20%20adversos%20foram%20de%20gravidade%20leve%20a%20moderada.%20%20Avalia%26%23xE7%3B%26%23xF5%3Bes%3A%20comum%3A%20aumento%20de%20peso%3B%20incomum%3A%20eletrocardiograma%20%20anormal.%20%20Transtornos%20card%26%23xED%3Bacos%3A%20comum%3A%20taquicardia%20sinusal%2C%20taquicardia%20atrioventricular%2C%20%20bloqueio%20de%20primeiro%20grau%2C%20bloqueio%20de%20ramo%2C%20bradicardia%3B%20incomum%3A%20%20palpita%26%23xE7%3B%26%23xF5%3Bes%2C%20arritmia%20sinusal.%20%20Transtornos%20oculares%3A%20incomum%3A%20rota%26%23xE7%3B%26%23xE3%3Bo%20ocular.%20%20Transtornos%20gastrintestinais%3A%20comum%3A%20dor%20abdominal%20alta%2C%20boca%20seca%2C%20hipersecre%26%23xE7%3B%26%23xE3%3Bo%20%20salivar%2C%20v%26%23xF4%3Bmito.%20%20Transtornos%20gerais%3A%20comum%3A%20astenia%2C%20fadiga%3B%20incomum%3A%20edema.%20%20Transtornos%20do%20sistema%20imunol%26%23xF3%3Bgico%3A%20incomum%3A%20rea%26%23xE7%3B%26%23xE3%3Bo%20anafi%20l%26%23xE1%3Btica.%20%20Transtornos%20metab%26%23xF3%3Blicos%20e%20nutricionais%3A%20incomum%3A%20aumento%20do%20apetite%20%20Transtornos%20de%20m%26%23xFA%3Bsculo-esquel%26%23xE9%3Btico%20e%20de%20tecido%20conjuntivo%3A%20incomum%3A%20%20rigidez%20muscular.%20%20Transtornos%20do%20sistema%20nervoso%3A%20muito%20comum%3A%20cefal%26%23xE9%3Bia%3B%20comum%3A%20acatisia%2C%20%20vertigem%2C%20distonia%2C%20transtorno%20extrapiramidal%2C%20hipertonia%2C%20Parkinsonismo%2C%20%20seda%26%23xE7%3B%26%23xE3%3Bo%2C%20sonol%26%23xEA%3Bncia%2C%20tremor%3B%20incomum%3A%20vertigem%20postural%2C%20discinesia%2C%20%20convuls%26%23xE3%3Bo%20do%20tipo%20grande%20mal%2C%20s%26%23xED%3Bncope.%20%20Transtorno%20psiqui%26%23xE1%3Btrico%3A%20incomum%3A%20pesadelo.%20%20Transtorno%20do%20sistema%20reprodutor%20e%20de%20mamas%3A%20incomum%3A%20amenorr%26%23xE9%3Bia%2C%20%20secre%26%23xE7%3B%26%23xE3%3Bo%20mam%26%23xE1%3Bria%2C%20disfun%26%23xE7%3B%26%23xE3%3Bo%20er%26%23xE9%3Btil%2C%20galactorr%26%23xE9%3Bia%2C%20ginecomastia%2C%20menstrua%26%23xE7%3B%26%23xE3%3Bo%20%20irregular.%20%20Transtornos%20vasculares%3A%20comum%3A%20hipotens%26%23xE3%3Bo%20ortost%26%23xE1%3Btica%3B%20incomum%3A%20hipotens%26%23xE3%3Bo%2C%20%20isquemia.%20%20Pacientes%20idosos%20%20A%20seguran%26%23xE7%3Ba%20de%20Invega%20foi%20avaliada%20em%2081%20pacientes%20idosos%20com%20esquizofrenia%20%20(idade%20%3D65%20anos)%20que%20receberam%20doses%20fl%20ex%26%23xED%3Bveis%20(n%3D76)%20ou%20fi%20xas%20%20(n%3D5)%20de%20Invega%20na%20faixa%20de%203%20a%2012%20mg%20uma%20vez%20ao%20dia%20por%20at%26%23xE9%3B%206%20semanas%20durante%20os%20estudos%20duplo-cegos%2C%20controlados%20com%20placebo.%20Embora%20esse%20%20conjunto%20de%20dados%20n%26%23xE3%3Bo%20permita%20uma%20compara%26%23xE7%3B%26%23xE3%3Bo%20direta%20sistem%26%23xE1%3Btica%20entre%20%20pacientes%20idosos%20e%20n%26%23xE3%3Bo%20idosos%2C%20o%20perfi%20l%20de%20seguran%26%23xE7%3Ba%20foi%20similar%20nas%20duas%20%20popula%26%23xE7%3B%26%23xF5%3Bes.%20No%20entanto%2C%20com%20base%20nesses%20dados%20limitados%20e%20consistente%20%20com%20a%20pr%26%23xE1%3Btica%20cl%26%23xED%3Bnica%20geral%2C%20n%26%23xE3%3Bo%20%26%23xE9%3B%20poss%26%23xED%3Bvel%20excluir%20uma%20maior%20sensibilidade%20%20de%20indiv%26%23xED%3Bduos%20mais%20idosos%20a%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas.%20%20Eventos%20de%20interesse%20particular%20para%20a%20classe%20%20Sintomas%20extrapiramidais%3A%20os%20dados%20agrupados%20dos%203%20estudos%20cl%26%23xED%3Bnicos%20de%20%20dose%20fi%20xa%2C%20controlados%20com%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20revelaram%20%20diferen%26%23xE7%3Bas%20nos%20eventos%20extrapiramidais%20que%20surgiram%20com%20o%20tratamento%2C%20%20comparando-se%20o%20placebo%20(11%25)%20e%20Invega%203%20e%206%20mg%20(13%25%20e%2010%25%2C%20%20respectivamente).%20Sintomas%20extrapiramidais%20relacionados%20%26%23xE0%3B%20dose%20foram%20%20observados%20nas%20duas%20dosagens%20maiores%20de%20Invega%20(25%25%20e%2026%25%20para%20%20as%20doses%20de%209%20e%2012%20mg%2C%20respectivamente).%20Os%20sintomas%20extrapiramidais%20%20inclu%26%23xED%3Bram%20uma%20an%26%23xE1%3Blise%20agrupada%20dos%20seguintes%20termos%3A%20discinesia%2C%20distonia%2C%20%20hipercinesia%2C%20Parkinsonismo%20e%20tremor.%20%20Ganho%20de%20peso%3A%20nos%20dados%20agrupados%20dos%203%20estudos%20cl%26%23xED%3Bnicos%20de%20dose%20fi%20xa%2C%20%20controlados%20com%20placebo%2C%20de%206%20semanas%20de%20dura%26%23xE7%3B%26%23xE3%3Bo%2C%20as%20propor%26%23xE7%3B%26%23xF5%3Bes%20de%20%20pacientes%20que%20atingiram%20o%20crit%26%23xE9%3Brio%20de%20ganho%20de%20peso%20%3D7%25%20do%20peso%20corporal%20%20foram%20comparadas%20e%20revelaram%20uma%20incid%26%23xEA%3Bncia%20similar%20de%20ganho%20de%20peso%20%20para%20Invega%203%20mg%20(7%25)%20e%206%20mg%20(6%25)%20em%20compara%26%23xE7%3B%26%23xE3%3Bo%20ao%20placebo%20(5%25)%20e%20%20uma%20maior%20incid%26%23xEA%3Bncia%20de%20ganho%20de%20peso%20para%209%20mg%20(9%25)%20e%2012%20mg%20(9%25).%20%20Exames%20laboratoriais%3A%20Prolactina%20s%26%23xE9%3Brica%3A%20com%20base%20nos%20dados%20agrupados%20%20dos%203%20estudos%20cl%26%23xED%3Bnicos%20de%20dose%20fi%20xa%2C%20controlados%20com%20placebo%2C%20de%206%20semanas%20%20de%20dura%26%23xE7%3B%26%23xE3%3Bo%2C%20foram%20observados%20aumentos%20medianos%20na%20prolactina%20%20s%26%23xE9%3Brica%20em%20pacientes%20de%20ambos%20os%20sexos%20que%20receberam%20Invega.%20Os%20%20aumentos%20m%26%23xE9%3Bdios%20m%26%23xE1%3Bximos%20da%20concentra%26%23xE7%3B%26%23xE3%3Bo%20de%20prolactina%20s%26%23xE9%3Brica%20foram%20%20observados%2C%20em%20geral%2C%20no%2015%26%23xBA%3B%20dia%20do%20tratamento%2C%20mas%20permaneceram%20acima%20%20dos%20n%26%23xED%3Bveis%20da%20linha%20de%20base%20ao%20fi%20nal%20do%20estudo.%20%20Estudos%20Cl%26%23xED%3Bnicos%3A%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%26%23xE0%3B%20droga%20em%20estudo%20de%20longa-dura%26%23xE7%3B%26%23xE3%3Bo%2C%20%20controlado%20por%20placebo%3A%20a%20seguran%26%23xE7%3Ba%20de%20Invega%20foi%20tamb%26%23xE9%3Bm%20avaliada%20em%20%20estudo%20de%20longa-dura%26%23xE7%3B%26%23xE3%3Bo%2C%20delineado%20para%20avaliar%20manuten%26%23xE7%3B%26%23xE3%3Bo%20do%20efeito%20de%20%20Invega%20em%20adultos%20com%20esquizofrenia.%20Em%20geral%2C%20os%20tipos%2C%20freq%26%23xFC%3B%26%23xEA%3Bncias%20e%20%20gravidades%20das%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%26%23xE0%3B%20droga%2C%20relatados%20durante%20a%20fase%20inicial%2C%20%20aberta%2C%20de%2014%20semanas%20deste%20estudo%2C%20foram%20compar%26%23xE1%3Bveis%20%26%23xE0%3B%20aqueles%20relatados%20%20no%20estudo%20de%20curto%20prazo%2C%20por%2006%20semanas%2C%20com%20dose-fi%20xa%2C%20controlado%20%20por%20placebo.%20As%20rea%26%23xE7%3B%26%23xF5%3Bes%20adversas%20%26%23xE0%3B%20droga%20relatadas%20durante%20a%20fase%20de%20%20longo%20prazo%2C%20duplo-cega%20deste%20estudo%20foram%20similares%20em%20tipo%20e%20gravidade%20%20%26%23xE0%3Bs%20observadas%20na%20fase%20aberta%2C%20inicial%2C%20com%20dura%26%23xE7%3B%26%23xE3%3Bo%20de%2014%20semanas%3B%20entretanto%2C%20%20em%20geral%20ocorreram%20em%20freq%26%23xFC%3B%26%23xEA%3Bncias%20menores.%20%20Informa%26%23xE7%3B%26%23xF5%3Bes%20de%20seguran%26%23xE7%3Ba%20relacionados%20%26%23xE0%3B%20risperidona%3A%20a%20paliperidona%20corresponde%20%20a%20um%20metab%26%23xF3%3Blito%20ativo%20da%20risperidona.%20O%20perfi%20l%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20da%20%20droga%20e%20as%20propriedades%20farmacocin%26%23xE9%3Bticas%20de%20Invega%20s%26%23xE3%3Bo%20consideralvemente%20%20diferentes%20das%20observadas%20com%20formula%26%23xE7%3B%26%23xF5%3Bes%20de%20libera%26%23xE7%3B%26%23xE3%3Bo%20imediata%2C%20para%20admnistra%26%23xE7%3B%26%23xE3%3Bo%20via%20oral%2C%20contendo%20risperidona.%20As%20informa%26%23xE7%3B%26%23xF5%3Bes%20de%20seguran%26%23xE7%3Ba%20%20relatadas%20com%20risperidona%20em%20estudos%20cl%26%23xED%3Bnicos%20e%20em%20experi%26%23xEA%3Bncia%20%20p%26%23xF3%3Bs-comercializa%26%23xE7%3B%26%23xE3%3Bo%20que%20n%26%23xE3%3Bo%20foram%20relatadas%20com%20Invega%20podem%20ser%20%20encontradas%20na%20bula%20de%20medicamentos%20contendo%20risperidona.%0A%0A%0A%0A%3C%2Fp%3E%3Ch2%3EINVEGA%20%26%23x2013%3B%20Posologia%3C%2Fh2%3E%0A%3Cp%3EAdultos%20(idade%20acima%20de%2018%20anos)%20%20A%20dose%20de%20Invega%20recomendada%20%26%23xE9%3B%20de%206%20mg%20uma%20vez%20ao%20dia%2C%20por%20via%20oral%2C%20%20administrado%20pela%20manh%26%23xE3%3B%20com%20ou%20sem%20alimentos.%20N%26%23xE3%3Bo%20%26%23xE9%3B%20necess%26%23xE1%3Brio%20titular%20%20a%20dose%20inicial.%20Alguns%20pacientes%20podem%20se%20benefi%20ciar%20de%20doses%20mais%20altas%20%20ou%20mais%20baixas%20dentro%20da%20faixa%20recomendada%20de%203%20a%2012%20mg%20uma%20vez%20ao%20dia.%20%20Se%20indicados%2C%20os%20ajustes%20da%20dose%20podem%20ser%20feitos%20ap%26%23xF3%3Bs%20reavalia%26%23xE7%3B%26%23xE3%3Bo%20cl%26%23xED%3Bnica.%20%20Quando%20aumentos%20de%20dose%20s%26%23xE3%3Bo%20indicados%2C%20recomenda-se%20aumentos%20de%203%20%20mg%2Fdia%20e%20devem%20geralmente%20ocorrer%20em%20intervalos%20maiores%20do%20que%205%20dias.%20%20Pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20%20N%26%23xE3%3Bo%20%26%23xE9%3B%20necess%26%23xE1%3Brio%20ajustar%20a%20dose%20em%20pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20hep%26%23xE1%3Btica%20%20leve%20%26%23xE0%3B%20moderada.%20Invega%20n%26%23xE3%3Bo%20foi%20estudado%20em%20pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20%20hep%26%23xE1%3Btica%20grave.%20%20Pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20renal%20%20Para%20pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20renal%20leve%20(depura%26%23xE7%3B%26%23xE3%3Bo%20da%20creatinina%20%3D50%20a%20%20%26lt%3B%2080%20mL%2Fmin)%2C%20a%20dose%20inicial%20recomendada%20%26%23xE9%3B%203%20mg%20uma%20vez%20ao%20dia.%20A%20dose%20%20pode%20ser%20aumentada%20para%206%20mg%20uma%20vez%20ao%20dia%20baseados%20na%20tolerabilidade%20%20e%20resposta%20cl%26%23xED%3Bnica.%20%20Para%20pacientes%20com%20insufi%20ci%26%23xEA%3Bncia%20renal%20moderada%20a%20grave%20(depura%26%23xE7%3B%26%23xE3%3Bo%20da%20%20creatinina%20%3D10%20a%20%26lt%3B%2050%20mL%2Fmin)%2C%20a%20dose%20recomendada%20%26%23xE9%3B%203%20mg%20uma%20vez%20ao%20%20dia.%20Como%20Invega%20n%26%23xE3%3Bo%20foi%20estudado%20em%20pacientes%20com%20depura%26%23xE7%3B%26%23xE3%3Bo%20de%20%20creatinina%20%26lt%3B%2010%20mL%2Fmin%20%2C%20n%26%23xE3%3Bo%20se%20recomenda%20o%20uso%20nestes%20pacientes.%20%20Pacientes%20idosos%20%20As%20recomenda%26%23xE7%3B%26%23xF5%3Bes%20posol%26%23xF3%3Bgicas%20para%20pacientes%20idosos%20com%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal%20%20normal%20(%3D%2080%20mL%2Fmin)%20s%26%23xE3%3Bo%20as%20mesmas%20que%20as%20para%20adultos%20com%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal%20%20normal.%20No%20entanto%2C%20como%20os%20pacientes%20idosos%20podem%20ter%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal%20%20diminu%26%23xED%3Bda%2C%20pode%20ser%20necess%26%23xE1%3Brio%20ajustar%20a%20dose%20de%20acordo%20com%20o%20estado%20da%20%20fun%26%23xE7%3B%26%23xE3%3Bo%20renal.%20%20Crian%26%23xE7%3Bas%20%20A%20seguran%26%23xE7%3Ba%20e%20a%20efi%20c%26%23xE1%3Bcia%20de%20Invega%20n%26%23xE3%3Bo%20foram%20avaliadas%20em%20pacientes%20%20com%20idade%20inferior%20a%2018%20anos.%20%20Outras%20popula%26%23xE7%3B%26%23xF5%3Bes%20especiais%20%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20recomenda%26%23xE7%3B%26%23xE3%3Bo%20para%20ajuste%20da%20dose%20de%20Invega%20em%20fun%26%23xE7%3B%26%23xE3%3Bo%20do%20%20sexo%2C%20ra%26%23xE7%3Ba%20ou%20tabagismo.%0A%0A%0A%0A%3C%2Fp%3E%3Ch2%3ESuper%20dosagem%3C%2Fh2%3E%0A%3Cp%3ESintomas%20%20Em%20geral%2C%20os%20sinais%20e%20sintomas%20esperados%20s%26%23xE3%3Bo%20aqueles%20resultantes%20de%20uma%20%20exacerba%26%23xE7%3B%26%23xE3%3Bo%20dos%20efeitos%20farmacol%26%23xF3%3Bgicos%20conhecidos%20da%20paliperidona%2C%20isto%20%20%26%23xE9%3B%2C%20sonol%26%23xEA%3Bncia%20e%20seda%26%23xE7%3B%26%23xE3%3Bo%2C%20taquicardia%20e%20hipotens%26%23xE3%3Bo%2C%20prolongamento%20QT%20e%20%20sintomas%20extrapiramidais.%20No%20caso%20de%20superdose%20aguda%2C%20a%20possibilidade%20%20de%20envolvimento%20de%20v%26%23xE1%3Brios%20f%26%23xE1%3Brmacos%20deve%20ser%20considerada.%20%20Tratamento%20%20Ao%20avaliar%20a%20necessidade%20de%20tratamento%20e%20a%20recupera%26%23xE7%3B%26%23xE3%3Bo%20deve-se%20considerar%20%20a%20natureza%20da%20libera%26%23xE7%3B%26%23xE3%3Bo%20prolongada%20do%20medicamento.%20N%26%23xE3%3Bo%20h%26%23xE1%3B%20ant%26%23xED%3Bdoto%20%20espec%26%23xED%3Bfi%20co%20para%20a%20paliperidona.%20Medidas%20gerais%20de%20suporte%20devem%20%20ser%20adotadas.%20Estabelecer%20e%20manter%20as%20vias%20a%26%23xE9%3Breas%20e%20garantir%20oxigena%26%23xE7%3B%26%23xE3%3Bo%20%20e%20ventila%26%23xE7%3B%26%23xE3%3Bo%20adequadas.%20O%20monitoramento%20cardiovascular%20deve%20ser%20iniciado%20%20imediatamente%20e%20deve%20incluir%20monitoramento%20eletrocardiogr%26%23xE1%3Bfico%20cont%26%23xED%3Bnuo%20para%20poss%26%23xED%3Bveis%20arritmias.%20Hipotens%26%23xE3%3Bo%20e%20colapso%20circulat%26%23xF3%3Brio%20devem%20%20ser%20tratados%20com%20medidas%20apropriadas%20tais%20como%20l%26%23xED%3Bquidos%20intravenosos%20e%2F%20%20ou%20agentes%20simpatomim%26%23xE9%3Bticos.%20A%20lavagem%20g%26%23xE1%3Bstrica%20(ap%26%23xF3%3Bs%20intuba%26%23xE7%3B%26%23xE3%3Bo%20se%20o%20%20paciente%20estiver%20inconsciente)%20e%20a%20administra%26%23xE7%3B%26%23xE3%3Bo%20de%20carv%26%23xE3%3Bo%20ativado%20junto%20%20com%20um%20laxativo%20devem%20ser%20consideradas.%20Na%20presen%26%23xE7%3Ba%20de%20sintomas%20extrapiramidais%20%20graves%2C%20agentes%20anticolin%26%23xE9%3Brgicos%20devem%20ser%20administrados.%20%20Uma%20supervis%26%23xE3%3Bo%20cuidadosa%20e%20o%20monitoramento%20devem%20continuar%20at%26%23xE9%3B%20a%20recupera%26%23xE7%3B%26%23xE3%3Bo%20do%20paciente.%3C%2Fp%3E%0A%3Ch2%3ECaracteristicas%20farmalogicas%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%20%20%20%20%20%20%20%20%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Famp-ad%3E%0A%3Ch2%3EResultados%20de%20eficacia%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EUsos%20em%20idosos%2C%20crian%26%23xE7%3Bas%20e%20em%20outros%20grupos%20de%20risco%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EArmazenagem%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EDizeres%20legais%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%20%20%20%20%20%20%20%20%3Camp-ad%20width%3D%22300%22%20height%3D%22250%22%20type%3D%22adsense%22%20data-ad-client%3D%22ca-pub-2735105532917738%22%20data-ad-slot%3D%222092927135%22%20data-auto-format%3D%22auto%22%20data-full-width-responsive%3D%22true%22%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20overflow%3E%3C%2Fdiv%3E%0A%20%20%20%20%20%20%20%20%3C%2Famp-ad%3E%0A%3Ch2%3EINVEGA%20%26%23x2013%3B%20Bula%20para%20o%20paciente%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%3Ch2%3EData%20da%20bula%3C%2Fh2%3E%0A%3Cp%3EInforma%26%23xE7%3B%26%23xE3%3Bo%20n%26%23xE3%3Bo%20dispon%26%23xED%3Bvel%20para%20esta%20bula.%3C%2Fp%3E%0A%09%09%09%09%09%09
Ame
Sim
ApresentarPrecoDePor
Sim
custom_label_0
campanha
MedicamentoControlado
Sim
Cashback
Não
Antibiotico
Não
Generico
Não

Tributos e contexto fiscal

Escolha o estado para ver os tributos deste produto:
Preferência salva neste navegador; confirme o destino da operação.

NCM, CEST e tributos são referências fiscais brasileiras e podem não se aplicar em outros países.

Selecione a UF nesta seção para consultar a estimativa IBPT.

IBS/CBS: o cClassTrib acima vem do enquadramento do NCM; percentuais dependem da operação, regime, data e destino.

Medicamento — dados oficiais

Medicamento
INVEGA 200 MG/ML SUS INJ LIB PROL IM CT 1 SER PREENC PLAS TRANS COC X 1,315 ML + 2 AGU
Princípio ativo
PALMITATO DE PALIPERIDONA
Laboratório
JANSSEN-CILAG FARMACEUTICA LTDA
Registro ANVISA
1123633980170
Classe terapêutica
N5A1 - ANTIPSICÓTICOS ATÍPICOS
Tipo
Novo
Tarja
Tarja Vermelha
PIS/COFINS
Lista negativa (PIS/COFINS monofásico, sem crédito presumido)

Fonte: CMED/ANVISA, lista de preços de medicamentos publicada em 09/10/2026. Confirme a tributação com seu contador.

Invega Trinza 263mg Suspensão Injetável de Liberação Prolongada 1 Seringa Preenchida + 2 Agulhas - Invega

Dados estruturados

Veja como a API devolve os dados de um produto.

Exemplo ilustrativo, igual em todas as páginas. Os dados reais deste código de barras vêm da API, com o seu token.

GET https://global.si5.com.br/index.php/api/produtos/123456788


            

Para chamar a API de verdade você usa um token pessoal — grátis até 30 consultas por dia.

Histórico de preços

Como o preço deste produto variou.

Preços de referência coletados em lojas online. Uma nova coleta acontece a cada cerca de 30 dias e sempre que o preço muda.

Último preçoR$ 7.572,99
Variação no período+10,0%
Menor / maiorR$ 6.884,99 / R$ 7.572,99
Coletas3
6.884,99 7.114,32 7.343,66 7.572,99 02/10/2026: R$ 6.884,99 (paguemenos.com.br) 11/10/2026: R$ 7.572,99 (araujo.vtexcommercestable.com.br) 15/10/2026: R$ 7.572,99 (drogariaricardoeletro.vtexcommercestable.com.br) 6.884,99 7.572,99 02/10 15/10
DataPreçoVariaçãoFonte
15/10/2026 R$ 7.572,99 primeira coleta drogariaricardoeletro.vtexcommercestable.com.br
11/10/2026 R$ 7.572,99 primeira coleta araujo.vtexcommercestable.com.br
02/10/2026 R$ 6.884,99 primeira coleta paguemenos.com.br

Valores informativos coletados de lojas online, sem garantia de que estejam atualizados. Não representam preço de venda do SI5 Global.